ArticleBMC complementary medicine and therapies2026
Unveiling the antioxidant and anticancer potential of local mediterranean olive and fig extracts against breast cancer.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Given the interest in dietary interventions against cancer, this study investigated the antioxidant and anticancer potential of nutraceuticals from key components of the mediterranean diet (MD) against breast cancer considering their rich polyphenolic content and antioxidant profile. Extracts from three Lebanese Ficus carica (FC) varieties Shatawi (Sh), Baqarati (Bq), Asali (As), and two local Olea europea (OE) varieties Green olive (GO) and Black olive (BO) were selected for evaluation based on their traditional dietary relevance and potential bioactivity. Methanolic extracts of these components were analyzed for their total polyphenolic content (TPC), anthocyanin content (TAC), and antioxidant activity. The anticancer effects of the single and combined agents were evaluated on 2 breast cancer cell lines (MCF-7 and MDA-MB-231) and non-tumorigenic intestinal epithelial cell line (FHs-74) using MTT assay and flow cytometry. FC and OE extracts were tested at concentration ranges (2–30 mg/ml and 0.3–2.4 mg/ml), respectively. We showed that OE extracts, particularly from BO, exhibited significantly higher TPC and three-times greater TAC than FC extracts. Compared to all FC extracts, BO extract demonstrated strong anticancer effects at 100-fold lower concentrations, especially against MCF-7 cells. Importantly, BO did not affect the viability of normal FHs-74 cells at doses up to 1.2 mg/mL. Interestingly, combination of FC and OE extracts particularly darker- colored varieties with higher TPC (Sh and BO) resulted in an enhanced 79% and 64% reduction of respectively MCF-7 and MDA-MB-231 BC cell line viability compared to single treatment. This dual treatment induced a greater increase in sub-G1 populations in MCF-7 cancer cells compared to BO alone. These findings highlight the therapeutic potential of Mediterranean fruit extracts, particularly BO and Sh, positioning them as promising candidates to support breast cancer treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.